PDSB PE Ratio & Valuation,Is PDSB Overvalued

PDSB Relative Valuation

PDSB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PDSB is overvalued; if below, it's undervalued.

Historical Valuation

PDS Biotechnology Corp (PDSB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.81. The fair price of PDS Biotechnology Corp (PDSB) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.00

Fair

-1.35

-1.17

EV/EBITDA

PDS Biotechnology Corp. (PDSB) has a current EV/EBITDA of -1.17. The 5-year average EV/EBITDA is -3.52. The thresholds are as follows: Strongly Undervalued below -11.07, Undervalued between -11.07 and -7.29, Fairly Valued between 0.26 and -7.29, Overvalued between 0.26 and 4.03, and Strongly Overvalued above 4.03. The current Forward EV/EBITDA of -1.17 falls within the Historic Trend Line -Fairly Valued range.

-1.25

EV/EBIT

PDS Biotechnology Corp. (PDSB) has a current EV/EBIT of -1.25. The 5-year average EV/EBIT is -3.32. The thresholds are as follows: Strongly Undervalued below -9.74, Undervalued between -9.74 and -6.53, Fairly Valued between -0.11 and -6.53, Overvalued between -0.11 and 3.10, and Strongly Overvalued above 3.10. The current Forward EV/EBIT of -1.25 falls within the Historic Trend Line -Fairly Valued range.

0.00

PDS Biotechnology Corp. (PDSB) has a current PS of 0.00. The 5-year average PS is 86.10. The thresholds are as follows: Strongly Undervalued below -665.75, Undervalued between -665.75 and -289.83, Fairly Valued between 462.02 and -289.83, Overvalued between 462.02 and 837.94, and Strongly Overvalued above 837.94. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

PDS Biotechnology Corp. (PDSB) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.59. The thresholds are as follows: Strongly Undervalued below -12.56, Undervalued between -12.56 and -8.58, Fairly Valued between -0.60 and -8.58, Overvalued between -0.60 and 3.39, and Strongly Overvalued above 3.39. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-1.43

P/FCF

PDS Biotechnology Corp. (PDSB) has a current P/FCF of -1.43. The 5-year average P/FCF is -2.06. The thresholds are as follows: Strongly Undervalued below -5.55, Undervalued between -5.55 and -3.81, Fairly Valued between -0.32 and -3.81, Overvalued between -0.32 and 1.42, and Strongly Overvalued above 1.42. The current Forward P/FCF of -1.43 falls within the Historic Trend Line -Fairly Valued range.

PDS Biotechnology Corp (PDSB) has a current Price-to-Book (P/B) ratio of 4.96. Compared to its 3-year average P/B ratio of 4.28 , the current P/B ratio is approximately 15.88% higher. Relative to its 5-year average P/B ratio of 4.11, the current P/B ratio is about 20.83% higher. PDS Biotechnology Corp (PDSB) has a Forward Free Cash Flow (FCF) yield of approximately -60.57%. Compared to its 3-year average FCF yield of -33.97%, the current FCF yield is approximately 78.28% lower. Relative to its 5-year average FCF yield of -24.57% , the current FCF yield is about 146.46% lower.

4.96

P/B

Median3y

4.28

Median5y

4.11

-60.57

FCF Yield

Median3y

-33.97

Median5y

-24.57

Competitors Valuation Multiple

The average P/S ratio for PDSB's competitors is 1361.83, providing a benchmark for relative valuation. PDS Biotechnology Corp Corp (PDSB) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PDSB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PDSB in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PDS Biotechnology Corp (PDSB) currently overvalued or undervalued?

What is PDS Biotechnology Corp (PDSB) fair value?

PDSB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of PDS Biotechnology Corp (PDSB) is between NaN to NaN according to relative valuation methord.

How does PDSB's valuation metrics compare to the industry average?

The average P/S ratio for PDSB's competitors is 1361.83, providing a benchmark for relative valuation. PDS Biotechnology Corp Corp (PDSB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for PDS Biotechnology Corp (PDSB) as of Dec 15 2025?

As of Dec 15 2025, PDS Biotechnology Corp (PDSB) has a P/B ratio of 4.96. This indicates that the market values PDSB at 4.96 times its book value.

What is the current FCF Yield for PDS Biotechnology Corp (PDSB) as of Dec 15 2025?

As of Dec 15 2025, PDS Biotechnology Corp (PDSB) has a FCF Yield of -60.57%. This means that for every dollar of PDS Biotechnology Corp’s market capitalization, the company generates -60.57 cents in free cash flow.

What is the current Forward P/E ratio for PDS Biotechnology Corp (PDSB) as of Dec 15 2025?

As of Dec 15 2025, PDS Biotechnology Corp (PDSB) has a Forward P/E ratio of -1.35. This means the market is willing to pay $-1.35 for every dollar of PDS Biotechnology Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for PDS Biotechnology Corp (PDSB) as of Dec 15 2025?

As of Dec 15 2025, PDS Biotechnology Corp (PDSB) has a Forward P/S ratio of 0.00. This means the market is valuing PDSB at $0.00 for every dollar of expected revenue over the next 12 months.

PDSB Valuation